Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists

QR Code

Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists

Hamish Courtney,1 Rahul Nayar,2 Chinnadorai Rajeswaran,3 Ravi Jandhyala 4 1Diabetes Department, Royal Victoria Hospital, Belfast, 2City Hospitals Sunderland NHS Foundation Trust, Sunderland, 3Department of Diabetes & Endocrinology, Mid Yorkshire NHS Trust, Dewsbury, 4Medical Affairs, Diabete...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Courtney H, Nayar R, Rajeswaran C, Jandhyala R
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2017
Sujets:	albiglutide dulaglutide exenatide liraglutide lixisenatide long-term Specialties of internal medicine RC581-951
Accès en ligne:	https://doaj.org/article/8a308f75e3eb4afeaa8d08e68d6d2edc
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Emerging role of GLP-1 receptor agonists in the treatment of obesity
par: Neff LM
Publié: (2010)

An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method
par: Martin AA, et autres
Publié: (2016)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
par: Knop FK, et autres
Publié: (2010)

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
par: Gurung T, et autres
Publié: (2015)

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
par: Marina V. Shestakova, et autres
Publié: (2017)

Priority areas in management of diabetes mellitus type 1 & 2 (following 47th EASD Annual Meeting)
par: Ivona Renata Yarek-Martynova, et autres
Publié: (2011)

When Inappropriate Use of Insulin is Dangerous: The Utility of C-Peptide Assay in the Era of Cardioprotective Antidiabetic Drugs
par: Volpe S, et autres
Publié: (2021)

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
par: Saunders WB, et autres
Publié: (2016)

Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review
par: Berlie H, et autres
Publié: (2012)

Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
par: Levin PA, et autres
Publié: (2017)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
par: Thompson AM, et autres
Publié: (2016)

Long-term outcomes following completion of a structured nutrition and exercise lifestyle intervention program for patients with metabolic syndrome
par: Joseph MS, et autres
Publié: (2018)

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
par: Marina Vladimirovna Shestakova
Publié: (2010)

Relationship Between Long-Term Objectively Measured Physical Activity and Glycemic Control in Type 2 Diabetes Mellitus Patients: A Prospective Cohort Study
par: Masuda H, et autres
Publié: (2021)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
par: Campbell RK, et autres
Publié: (2010)

Weight loss medications in Canada – a new frontier or a repeat of past mistakes?
par: Wharton S, et autres
Publié: (2017)

Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
par: Lee J, et autres
Publié: (2019)

Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE–/– Mice
par: Liu F, et autres
Publié: (2020)

Effects of liraglutide on lipolysis and the AC3/PKA/HSL pathway
par: Li Z, et autres
Publié: (2019)

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
par: Howell R, et autres
Publié: (2019)

Explore the Effect and Target of Liraglutide on Islet Function in Type 2 Diabetic Rats by miRNA Omics Technology
par: Guo Q, et autres
Publié: (2021)

Liraglutide and Insulin Have Contrary Effects on Adipogenesis of Human Adipose-Derived Stem Cells via Wnt Pathway
par: Liu H, et autres
Publié: (2020)

Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
par: Kedia N
Publié: (2011)

Key policy issues in long-term care
Publié: (2003)

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
par: Minara S. Shamkhalova, et autres
Publié: (2020)

Long-term care in developing countries ten case-studies /
Publié: (2003)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
par: Seewoodhary J, et autres
Publié: (2010)

Long-Term Symptoms among Hospitalized COVID-19 Patients 48 Weeks after Discharge—A Prospective Cohort Study
par: Martin Mølhave, et autres
Publié: (2021)

Dysregulation of DPP4 Is Associated with the AMPK/JAK2/STAT3 Pathway in Adipocytes Under Insulin Resistance Status and Liraglutide Intervention
par: Cheng F, et autres
Publié: (2019)

Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway
par: Yang P, et autres
Publié: (2019)

Genomewide Dam Methylation in <named-content content-type="genus-species">Escherichia coli</named-content> during Long-Term Stationary Phase
par: Lacey L. Westphal, et autres
Publié: (2016)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
par: Gagik R. Galstyan, et autres
Publié: (2017)

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
par: Chudleigh RA, et autres
Publié: (2020)

The Brown University long-term care quality letter
Publié: (1992)

Long-term living

RAPPROCHEMENT OF LONG-TERM FINANCIAL INTERESTS OF THE SHAREHOLDER AND THE MANAGEMENT OF THE COMPANY
par: S. I. Lutsenko
Publié: (2020)

Hypospadias: clinical approach, surgical technique and long-term outcome
par: Pier Luca Ceccarelli, et autres
Publié: (2021)

Long Term Neutron Activation in JET DD Operation
par: Žohar Andrej, et autres
Publié: (2021)

Amantadine reduces glucagon and enhances insulin secretion throughout the oral glucose tolerance test: central plus peripheral nervous system mechanisms
par: Fuad Lechin, et autres
Publié: (2009)

Short-Term to Long-Term Plasticity Transition Behavior of Memristive Devices with Low Power Consumption via Facilitating Ionic Drift of Implanted Lithium
par: Young Pyo Jeon, et autres
Publié: (2021)